Cole M
Latest
- Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition
- Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): Study protocol for a single-arm, single-stage, phase II trial
- Drooling Reduction Intervention randomised trial (DRI): Comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability
- A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): Study protocol
- Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
- A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial
- PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
- Abstract 4651: Characterization of the clinical pharmacokinetics of actinomycin D and the influence of pharmacogenetic variation in children with cancer
- Abstract 5457: Cytarabine leaves a mutational fingerprint in relapsing leukemia
- Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia
- Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer
- Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
- Population pharmacokinetic investigation of actinomycin-D in children and young adults
- Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma
- MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma
- Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients
- Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy
- Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
- Abstract 3442: TP53 mutations in favorable risk WNT subtype medulloblastomas
- TP53 mutations in favorable-risk wnt/wingless-subtype medulloblastomas
- Rapid diagnosis of medulloblastoma molecular subgroups
- Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival
- Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival
- Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials
- Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose
- Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate
- Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
- High Frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma
- Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
- Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients
- Screening infants for neuroblastoma: The parents' perspective
- Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
- Human renal function maturation: A quantitative description using weight and postmenstrual age
- Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
- Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
- Mismatch repair defects in childhood acutelymphoblastic leukaemia at diagnosis and relapse
- Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer
- Pharmacogenetics and metabolism of cyclophosphamidein paediatric cancer patients
- p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma
- Quantitative assessment of mixed chimerism in allogeneic stem cell transplant patients: A comparison of molecular genetic and cytogenetic approaches
- Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children's Cancer Study Group
- Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children′s Cancer Study Group
- Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?
- A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer
- Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group Study
- Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics
- Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
- The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system
- Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
- A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia
- OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age
- Cyclophosphamide metabolism in children with Fanconi's anaemia
- Cyclophosphamide metabolism in children with Fanconi's anaemia
- The effect of fluconazole on cyclophosphamide metabolism in children
- A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children
- Neonatal vitamin K administration and childhood cancer in the north of England: Retrospective case-control study
- Cyclophosphamide pharmacokinetics in children
- Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
- Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults
- Screening for wilms' tumour in patients with aniridia, Beckwith syndrome, or hemihypertrophy
- The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
- Expression of µ Class Glutathione S-Transferase Correlates with Event-free Survival in Childhood Acute Lymphoblastic Leukemia
- Screening infants for neuroblastoma: The parents' perspective in false-positive cases
- Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio
- False positive results in a neuroblastoma screening programme
- Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation
- Creatinine related reference ranges for urinary homovanillic acid and vanillylmandelic acid at 6 months of age
- Screening for neuroblastoma in the north of England
- A pilot study of screening for neuroblastoma in the north of England
- Cot mattresses and sudden infant death syndrome
- Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis